Adverse neonatal effects of maternal labetalol treatment.
Two infants with features of severe beta adrenergic blockade, pericardial effusions, and myocardial hypertrophy were born to mothers receiving long term treatment with oral labetalol for hypertension in pregnancy. Labetalol was implicated in the aetiology of these problems. Pericardial effusion and myocardial hypertrophy have not been associated with labetalol toxicity in neonates.
Crooks
B N
BN
Newcastle Neonatal Service, Royal Victoria Infirmary, Newcastle upon Tyne.
Deshpande
S A
SA
Hall
C
C
Platt
M P
MP
Milligan
D W
DW
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D006332:Cardiomegaly / Q000139:chemically induced / Q000151:congenital* / Q000188:drug therapy; D004280:Dobutamine / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D005934:Glucagon / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007741:Labetalol / Q000009:adverse effects* / Q000627:therapeutic use; D009638:Norepinephrine / Q000627:therapeutic use; D010490:Pericardial Effusion / Q000139:chemically induced / Q000151:congenital* / Q000188:drug therapy; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011297:Prenatal Exposure Delayed Effects
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D004280:Dobutamine; D005934:Glucagon; D007741:Labetalol; D004298:Dopamine; D009638:Norepinephrine